
Annual report 2022
added 08-16-2022
Happiness Biotech Group Limited EBITDA 2011-2026 | HAPP
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Happiness Biotech Group Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -55.7 M | 2.41 M | 16.1 M | 22.5 M | 20.4 M | 17.3 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.5 M | -55.7 M | 3.84 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
BioNTech SE
BNTX
|
15.3 B | $ 95.5 | -3.88 % | $ 27.2 B | ||
|
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
232 M | $ 22.35 | 0.72 % | $ 3.7 B | ||
|
Galapagos NV
GLPG
|
-166 M | $ 28.39 | -0.13 % | $ 2.69 B | ||
|
Grifols, S.A.
GRFS
|
595 M | $ 8.27 | 0.49 % | $ 6.83 B | ||
|
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 3.5 | 5.42 % | $ 5.76 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | ||
|
InflaRx N.V.
IFRX
|
-37.3 M | $ 1.97 | -7.51 % | $ 152 M | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-62.4 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
-190 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-11.5 M | $ 23.42 | -0.3 % | $ 2.98 B | ||
|
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
-70 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-29.5 M | - | 17.91 % | $ 11.1 M | ||
|
Innate Pharma S.A.
IPHA
|
-47.8 M | $ 1.4 | -2.1 % | $ 235 M | ||
|
CRISPR Therapeutics AG
CRSP
|
-645 M | $ 52.38 | -2.24 % | $ 4.71 B | ||
|
Avenue Therapeutics
ATXI
|
-3.08 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-262 M | $ 1.64 | 4.46 % | $ 436 M | ||
|
Inventiva S.A.
IVA
|
-52.1 M | $ 5.42 | 2.85 % | $ 138 M | ||
|
AVROBIO
AVRO
|
10.8 M | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M | ||
|
Завод ДИОД
DIOD
|
85.9 M | - | - | - | ||
|
Фармсинтез
LIFE
|
-22.6 M | - | - | - | ||
|
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M |